How to read healthcare startup investment India data for October 2026: a reported $173 million, concentration in one deal and why trackers disagree.
What the reported French blood bank incident means for healthcare cybersecurity: contained impact, open questions and the business case for resilience.
What the end of Smith+Nephew’s J&J talks means for MedTech mergers and acquisitions: a second guidance cut, an Orthopaedics review and many open questions.
Why this Indian pharma acquisition matters: HRV Pharma’s purchase of Germany’s Phatebo diversifies an API business, but price and closing are undisclosed.
How to read healthcare startup investment India data for October 2026: a reported $173 million, concentration in one deal and why trackers disagree.
What the reported French blood bank incident means for healthcare cybersecurity: contained impact, open questions and the business case for resilience.
What the end of Smith+Nephew’s J&J talks means for MedTech mergers and acquisitions: a second guidance cut, an Orthopaedics review and many open questions.
Why this Indian pharma acquisition matters: HRV Pharma’s purchase of Germany’s Phatebo diversifies an API business, but price and closing are undisclosed.
Why the Lupin profit decline of 22.2% happened despite 14% sales growth: employee, manufacturing and depreciation costs, and what management has not said.
Why the Emcure FY27 guidance matters: revenue growth above 20%, margin expansion and a net cash target, with the debt and execution risks behind it.
What the Cerus RedeS result means for blood safety technology: a Phase 3 win on haemoglobin, an investigational US status and open commercial questions.
Why the pharmaceutical CDMO India segment is racing into peptides: Shilpa’s $50 million plan, what is set for December 2026 and what is undisclosed.
Why the Alembic US business drove Q2 FY27: formulations up 77%, margins up 520 bps and the question of whether the surge can last.
